These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8748631)

  • 21. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Parkinson disease. Directed use of modern therapy].
    Möller JC; Wächter T; Oertel WH
    MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine agonist-based strategies in the treatment of Parkinson's disease.
    Antonini A; Barone P
    Neurol Sci; 2008 Dec; 29 Suppl 5():S371-4. PubMed ID: 19381765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of early Parkinson's disease. Part 1.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 30. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
    Albanese A; Colosimo C
    Acta Neurol Scand; 2003 May; 107(5):349-55. PubMed ID: 12713527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine receptor agonists in the therapy of Parkinson's disease.
    Foley P; Gerlach M; Double KL; Riederer P
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1375-446. PubMed ID: 15480844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease.
    Cerri S; Blandini F
    Expert Opin Pharmacother; 2020 Dec; 21(18):2279-2291. PubMed ID: 32804544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.
    Blanchet PJ
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S21-6. PubMed ID: 10451756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease.
    Pirtosek Z; Merello M; Carlsson A; Stern G
    Adv Neurol; 1996; 69():535-40. PubMed ID: 8615177
    [No Abstract]   [Full Text] [Related]  

  • 39. Rationale for dopamine agonist use as monotherapy in Parkinson's disease.
    Schwarz J
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S27-33. PubMed ID: 15180135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease.
    Antonini A; Tolosa E; Mizuno Y; Yamamoto M; Poewe WH
    Lancet Neurol; 2009 Oct; 8(10):929-37. PubMed ID: 19709931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.